Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kendall's Tau Test01:16

Kendall's Tau Test

1.3K
Kendall's tau test, also known as the Kendall rank coefficient test, is a nonparametric method for assessing association between two variables. This test is particularly useful for identifying significant correlations when the distributions of the sample and population are unknown. Developed in 1938 by the British statistician Sir Maurice George Kendall, the tau coefficient (denoted as τ) serves as a rank correlation coefficient, with values ranging from -1 to +1.
A τ value of +1 indicates...
1.3K
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

319
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
319

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of plasma irisin levels with amyloid burden in the Alzheimer's disease spectrum.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Orexin, Sleep, and Cognition in Alzheimer Disease: Non-REM Oscillatory Activity and Neural Resilience.

Neurology·2026
Same author

Spatiotemporal dynamics of tau extent and load increase in Alzheimer's disease across four longitudinal cohorts.

Nature aging·2026
Same author

Performance of Alzheimer Disease Plasma Biomarkers in Patients With Prion Diseases.

Neurology·2026
Same author

Plasma proteomic profiles of Alzheimer's disease and neurodegeneration in African cohorts.

Nature communications·2026
Same author

Profiling Protein Aggregate Size Using Single-Molecule Array Technology.

Analytical chemistry·2026

Related Experiment Video

Updated: Apr 13, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.6K

Tailoring thresholds for interpreting plasma p-tau217 levels.

Jehyun Ahn1, Eun Hye Lee2,3, Heejin Yoo1

  • 1Alzheimer's Disease Convergence Research Center, Samsung Medical Center, Gangnam-gu, Korea (the Republic of).

Journal of Neurology, Neurosurgery, and Psychiatry
|May 24, 2025
PubMed
Summary

Plasma phosphorylated tau (p-tau) 217 tests show high accuracy for Alzheimer's disease (AD) diagnosis in impaired individuals. Tailored cut-offs are needed for unimpaired individuals, especially those under 65, for optimal AD detection.

Keywords:
ALZHEIMER'S DISEASEAMYLOIDBIOCHEMISTRYDEMENTIAPET

More Related Videos

Nuclear Magnetic Resonance Spectroscopy for the Identification of Multiple Phosphorylations of Intrinsically Disordered Proteins
12:47

Nuclear Magnetic Resonance Spectroscopy for the Identification of Multiple Phosphorylations of Intrinsically Disordered Proteins

Published on: December 27, 2016

19.0K
In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening
09:49

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

Published on: November 20, 2018

18.9K

Related Experiment Videos

Last Updated: Apr 13, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.6K
Nuclear Magnetic Resonance Spectroscopy for the Identification of Multiple Phosphorylations of Intrinsically Disordered Proteins
12:47

Nuclear Magnetic Resonance Spectroscopy for the Identification of Multiple Phosphorylations of Intrinsically Disordered Proteins

Published on: December 27, 2016

19.0K
In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening
09:49

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

Published on: November 20, 2018

18.9K

Area of Science:

  • Neurology
  • Biomarker Discovery
  • Alzheimer's Disease Diagnostics

Background:

  • Plasma phosphorylated tau (p-tau) 217 is a promising blood test for Alzheimer's disease (AD).
  • Its diagnostic performance across diverse patient subgroups needs further investigation.
  • This study evaluates p-tau217 utility in various cognitive and demographic groups.

Purpose of the Study:

  • To assess the diagnostic accuracy of plasma p-tau217 using a double cut-off approach.
  • To analyze performance across subgroups including cognitive status, age, sex, BMI, and APOE ε4 status.
  • To explore tailored cut-off strategies for specific populations.

Main Methods:

  • Analyzed plasma p-tau217 levels in cognitively unimpaired (CU) and cognitively impaired (CI) individuals.
  • Used double cut-offs to classify participants into amyloid-negative, intermediate, and amyloid-positive groups.
  • Evaluated diagnostic performance metrics (sensitivity, specificity, PPV, NPV) across subgroups.

Main Results:

  • Optimal p-tau217 cut-offs varied between CU and CI groups.
  • High diagnostic accuracy (sensitivity and specificity ≥90%) was observed in the CI group across all subgroups.
  • In the CU group, alternative cut-offs improved sensitivity to 85.0% and maintained specificity at 95.7% for individuals <65 years.

Conclusions:

  • Plasma p-tau217 shows robust diagnostic accuracy in cognitively impaired individuals.
  • Tailored cut-off thresholds are crucial for optimizing p-tau217 use in cognitively unimpaired populations.
  • Findings support plasma p-tau217 integration into clinical workflows for AD diagnostics and risk stratification.